Pharming announces refinancing of its existing debt by a single US$100 million debt facility on improved commercial terms
Pharming announces that it has completed a new US$100 million finance agreement with Orbimed Advisors.
This has been used to redeem the Amortizing Convertible Bonds due 2017/2018, and to refinance the Company’s senior debt facility with Silicon Valley Bank and Kreos Capital, together with the associated prepayment fees and the legal and other costs of the transaction. The loan, initially structured as a bridge facility will be replaced within 60 days by a full loan agreement with a maturity date of June 2021 under similar terms and conditions.
“We are delighted to announce that we have been able to improve the December 2016 funding of our RUCONEST® commercial rights acquisition further by refinancing the Senior Debt and redeeming the Amortizing Convertible Bonds on such excellent terms.’’- Dr Sijmen de Vries, CEO of Pharming